E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Untreated early stage Chronic Lymphocytic Leukaemia (CLL) (Binet stage A) with poor prognostic factors. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008958 |
E.1.2 | Term | Chronic lymphocytic leukaemia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the efficacy and tolerability of lenalidomide in the treatment of patients with poor risk early stage Chronic Lymphocytic Leukaemia (CLL). |
|
E.2.2 | Secondary objectives of the trial |
If treatment with lenalidomide is shown to be effective the secondary objective would be to conduct a randomised phase III trial to compare lenalidomide treatment with the current standard therapy (observation). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Binet stage A CLL • 2 or more risk factors: - Unmutated IgVH locus (≥98% homology to germline sequence) - CD38 expression (>7%) - Deletion of chromosome 11q22 (>20% by FISH) - Deletion of chromosome 17p13 (>10% by FISH) • Over 18 years old • Capable to provide written informed consent • ECOG performance status < 2 • Life expectancy > 2 years • Must agree to not share study lenalidomide with someone else • Must agree not to donate blood whilst taking the study drug and for one week after discontinuation of treatment • Female subjects of child bearing potential and all male subjects must agree to comply with the stipulations of the pregnancy prevention plan |
|
E.4 | Principal exclusion criteria |
• Current or recent (within the last 1 month) participation in another clinical trial investigation the action of an investigational medicinal product for the treatment of CLL • Pregnant or lactating • Known positivity for human immunodeficiency virus (HIV) types 1 or 2 • Prior history of malignancies, other than CLL, unless the subject was treated with curative intent and has been free of the disease for ≥3 years. Exceptions include the following: - Basal cell carcinoma of the skin - Squamous cell carcinoma of the skin - Carcinoma in situ of the cervix - Carcinoma in situ of the breast • Significantly abnormal renal or hepatic function - Creatinine clearance < 60ml/min (measured or calculated) - Serum aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN) - Serum bilirubin > 34μmol/l) • Laboratory tumour lysis syndrome according to the Cairo-Bishop classification. Subjects may be enrolled when these abnormalities have been corrected. • Peripheral neuropathy (grade ≥ 2) • Previous treatment for CLL • Previous treatment with Thalidomide or immunomodulatory derivative drugs (including lenalidomide) • Treatment with corticosteroids (for CLL or other indications) < 28 days from study entry • Evidence of Richter’s transformation • Unsupported absolute neutrophil count < 1x109/l or platelet count < 50x109/l not due to CLL • Active autoimmune haemolytic anaemia or thrombocytopenia • Any other medical or psychological condition that in the view of the investigator would be likely to impact compliance with the protocol or interfere with trial treatment. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Disease response assessment by achievement of Minimal Residual Disease (MRD) negative complete remission (CR). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the last visit (discontinuation or follow-up visit) of the last patient undergoing trial treatment. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |